Form 8-K - Current report:
SEC Accession No. 0001104659-24-130233
Filing Date
2024-12-19
Accepted
2024-12-19 17:01:38
Documents
15
Period of Report
2024-12-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2431516d1_8k.htm   iXBRL 8-K 30397
2 EXHIBIT 4.1 tm2431516d1_ex4-1.htm EX-4.1 81038
3 EXHIBIT 10.1 tm2431516d1_ex10-1.htm EX-10.1 27334
  Complete submission text file 0001104659-24-130233.txt   340842

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA mrsn-20241219.xsd EX-101.SCH 3012
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrsn-20241219_lab.xml EX-101.LAB 34240
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrsn-20241219_pre.xml EX-101.PRE 22357
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2431516d1_8k_htm.xml XML 3557
Mailing Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139 617-498-0020
Mersana Therapeutics, Inc. (Filer) CIK: 0001442836 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38129 | Film No.: 241564080
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)